General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. 340B, Vaccine issues. Issues related to TrumpRX.
2026 · 3rd Quarter (July 1 - Sep 30)
SANOFI, U.S.
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 20, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- SANOFI, U.S.
- Filing UUID
- b7d7e109-489f-411a-876c-aba1cc8dce70
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Pharmacy benefit manager reform proposals. Issues related to biopharmaceutical issues. Prescription drug pricing issues, particularly related to MFN.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs.
Monitor general tax issues related to international tax, vaccine excise taxes and orphan drug tax issues; implementation of PL 119-21.
Policies impacting vaccine access, disease prevention programs, and prescription drug labeling requirements.
Issues related to China WRT the BINSA bill. Monitoring 232 investigations.
Issues related to China WRT the BINSA bill.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.